Skip to main content
Premium Trial:

Request an Annual Quote

EMBL Purchases Genomatix's Software

NEW YORK (GenomeWeb News) — The European Molecular Biology Laboratory has installed genomics data mining and analysis tools from Genomatix Software in its Genomics Core Facility, the company said today.

The Munich-based company said that EMBL has purchased the company's Mining Station, which provides SNP detection and genotyping, copy number analysis, and small RNA analysis, and the Genome Analyzer, which conducts deep biological analysis of data from the GMS. Together, the systems offer an integrated solution for analyzing raw next-generation sequencing data.

EMBL's GeneCore is focused on studying the benefits and utilization of new technologies developed at EMBL, and on improving the quality, efficiency, and relevance of lab data.

Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.